drugset / Trial / NCT07135349
A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, open-label, multicenter phase II study to evaluate the efficacy and safety of BW-20507 in combination with PEG-IFNα in CHB patients
Timeline
- Start
- 2025-09-02
- Primary completion
- 2026-06-07
- Completion
- 2028-05-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BW-20507 | Unknown | — | — |
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | — | — |